PMDT

Programmatic Management of Drug-resistant TB (PMDT): While the causes of multi-drug resistant TB are similar in all high burden countries
(low adherence, weak DOTS, poor treatment compliance, inadequate drug supplies, direct transmission, etc.).

Multi-Drug Resistant TB

In 2014, approximately 480,000 people developed MDR-TB.  3.3% of new cases and 20% of previously treated patients develop MDR-TB.  It was estimated that only 41% of cases were notified that they had MDR-TB in 2014.  In low and middle income countries, access to quality TB services is often limited.  Since the beginning of TB CARE II in 2010, TB CARE II has worked to decrease MDR-TB.

TB CARE II DR TB Training Course Highlighted by CDC

Undefined

In July 2014, CDC’s Find TB Resources named Adherence to MDR-TB Treatment: The 5 A’s of Patient Support, an online course developed by the DR-TB Training Network, as its Highlight of the Month (http://findtbresources.cdc.gov/newsletter/newsletter14July.html).  This online course discusses key principles and steps to facilitate treatment adherence for patients with MDR-TB. The five A's presented in the course are: assess, advise, agree, arrange, and assist.

TB CARE II LAUNCHES COUNTRY PROGRAM IN SOUTH AFRICA FOR FY2015

Undefined

TB CARE II is excited to announce that it will be expanding its field support presence into South Africa for FY2015.  TB CARE II will build on the activities and approaches utilized by the USAID TB Program South Africa, also implemented by University Research Co., LLC (URC), which from 2009-2014 has supported the National Department of Health (NDOH) in improving early case detection, increasing access to diagnostics, ensuring treatment support for patients on TB treatment and ensuring that there is provision of appropriate and timely HIV care for TB patients and ART treatment for all TB/HIV

TB CARE II Bangladesh Celebrates Its Grantees in New Spotlight

Undefined

As a component of the project, TB CARE II Bangladesh supports nongovernmental, community based organizations (NGOs) in urban and rural areas with TB case notification rates below the national average to increase detection and management of TB and MDR TB services
and to improve community knowledge and awareness of TB and MDR TB. The geographic coverage varied under different waves of grants as indicated in the table below.Since April 2012, TB CARE II has supported 11 grantees for periods of one-to-two years each.

Community Programmatic Management of Drug Resistant Tuberculosis Planning Tool

Undefined

The community MDR TB planning tool focuses on operationalizing implementation of MDR TB community level interventions, drawing on information gained from the experience of several countries implementing a community model to deliver MDR TB services to patients.

The tool provides a situation analysis table to facilitate understanding of the health system context and model to provide MDR TB services in country, and considers TB and MDR TB country/district burden and the resources available in order to identify gaps in provision of MDR TB services.

Cover page of the Community Programmatic Management of Drug Resistant Tuberculosis Planning Toolkit

URC Participates in the 44th World Conference on Lung Health

Undefined

URC will again have a significant presence at this year’s Union World Conference on Lung Health from October 30–November 3 in Paris, France. In many of the 22 countries that account for more than 80% of TB cases worldwide, we are supporting national TB programs through innovative approaches to address systemic barriers to effective prevention and treatment. The conference provides an opportunity to share our TB work with thousands of health care professionals, researchers, and advocates.

Below is a list of our activities. We look forward to seeing you there or interacting with you on Twitter @urcchs using #LungHealth

- See more at: http://www.urc-chs.com/recent/news?newsItemID=374#sthash.9tWg43fj.dpuf

URC will again have a significant presence at this year’s Union World Conference on Lung Health from October 30–November 3 in Paris, France. In many of the 22 countries that account for more than 80% of TB cases worldwide, we are supporting national TB programs through innovative approaches to address systemic barriers to effective prevention and treatment. The conference provides an opportunity to share our TB work with thousands of health care professionals, researchers, and advocates.

Information and resources from URC’s TB projects in South Africa, Swaziland, Georgia, Malawi, Bangladesh, Vietnam, Indonesia and Cambodia will be on display, along with URC’s global TB CARE II project at the URC booth. 

Please see attached newsletter or visit the URC web page at http://www.urc-chs.com/recent/news?newsItemID=374 for more information.

 

TB CARE II Bangladesh: Changing Lives of MDR TB Patients

Undefined
Improving management of Multi-Drug-resistant TB (MDR TB) is a special focus of the TB CARE II project. It is estimated that there are 3,800 MDR TB cases annually in Bangladesh. A large proportion of these cases remain undetected and untreated, potentially increasing the risk of infection in the community.
 
It is not possible to combat the threat of MDR TB without a synchronized effort to expand national capacity both for diagnosis and treatment. To this end, the TB CARE II project started two new interventions in 2012. The introduction of Gene Xpert technology has been helping a large number of suspected patients with correct and faster diagnosis of drug resistant TB. The community based approach for management has significantly reduced treatment delays by shortening hospital stays and allowing the patients extended time at home to complete their treatment.
 
These efforts resulted in a substantial increase in the enrolment of MDR TB patients in treatment in less than two years.
This booklet titled ‘Changing Lives of MDR TB Patients’ has been prepared to highlight the impact of MDR TB on patients and their families and to demonstrate the acievements that have been made in improving systems of care. The stories epitomize the trials and tribulations that transpire in the lives of MDR TB patients. We hope these stories will generate awareness about MDR TB and inspire readers to join our fight against TB.
 

Pages